Screener
Adaptive Biotechnologies ADPT Mrd Business — Goodwill
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Adaptive Biotechnologies in its filing.
Tagged under the XBRL concept us-gaap:Goodwill.
The source filing: Adaptive Biotechnologies’s 10-K, filed February 26, 2026.
- Filed
- Feb 26, 2026, 4:31 PM EST
- Fiscal year
- FY2025
- Accession
- 0001193125-26-076902
There have been no changes in the carrying amount of goodwill since its recognition in 2015. In conjunction with our organizational realignment in 2024, we allocated goodwill among our two reporting units using a relative fair value approach. Goodwill allocated to the MRD and Immune Medicine reporting units as of December 31, 2025 was $96.4 million and $22.6 million, respectively.
Item 8. Financial Statements and Supplementary Data
FAQ
- What is Adaptive Biotechnologies's mrd business — goodwill?
- Adaptive Biotechnologies (ADPT) reported mrd business — goodwill of $96.4M in Q4 2025.
- What does mrd business — goodwill mean?
- This represents the intangible asset value recorded when the MRD business segment was acquired, reflecting the premium paid over the fair value of its net identifiable assets. It serves as a measure of the segment's long-term strategic value and potential for future economic benefits.
Ask your AI about Adaptive Biotechnologies's mrd business — goodwill.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude